Initial In Vivo Quantification of Tc-99m Sestamibi Uptake as a Function of Tissue Type in Healthy Breasts Using Dedicated Breast SPECT-CT.

Abstract

A pilot study is underway to quantify in vivo the uptake and distribution of Tc-99m Sestamibi in subjects without previous history of breast cancer using a dedicated SPECT-CT breast imaging system. Subjects undergoing diagnostic parathyroid imaging studies were consented and imaged as part of this IRB-approved breast imaging study. For each of the seven subjects, one randomly selected breast was imaged prone-pendant using the dedicated, compact breast SPECT-CT system underneath the shielded patient support. Iteratively reconstructed and attenuation and/or scatter corrected images were coregistered; CT images were segmented into glandular and fatty tissue by three different methods; the average concentration of Sestamibi was determined from the SPECT data using the CT-based segmentation and previously established quantification techniques. Very minor differences between the segmentation methods were observed, and the results indicate an average image-based in vivo Sestamibi concentration of 0.10 ± 0.16 μCi/mL with no preferential uptake by glandular or fatty tissues.

Department

Description

Provenance

Subjects

Citation

Published Version (Please cite this version)

10.1155/2012/146943

Publication Info

Mann, Steve D, Kristy L Perez, Emily KE McCracken, Jainil P Shah, Terence Z Wong and Martin P Tornai (2012). Initial In Vivo Quantification of Tc-99m Sestamibi Uptake as a Function of Tissue Type in Healthy Breasts Using Dedicated Breast SPECT-CT. J Oncol, 2012. p. 146943. 10.1155/2012/146943 Retrieved from https://hdl.handle.net/10161/12981.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Mann

Steven Mann

Assistant Professor of Radiology
Wong

Terence Z. Wong

Professor of Radiology
  1. Anatomic/functional oncologic Imaging: SPECT/CT, PET/CT, novel PET radiotracers

    2. Radiotheranostics, Radionuclide therapy of cancer, Radiation Therapy Planning

    3. Imaging biomarkers for guiding treatment strategies

    4. Multicenter clinical trial development (NCI National Clinical Trials Network)
Tornai

Martin Paul Tornai

Adjunct Associate Professor in the Department of Radiology

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.